Manufacturing and Supply, page-36

My thoughts were more towards the 2018/19 chronic and episodic migraine treatment game changers since Avinar say they re-evaluated the US migraine market. Preventative treatments from Amgen/Novartis, Lilly, and Teva approved this year followed early next year with as needed treatments for episodic migraine from Allergen, Alder and Biohaven.^1,2

AVP-825 (ONZETRA® Xsail® was introduced to fill an unmet need of fast-acting, non-oral medication option for migraine. Trial results support this, see review and expert opinion.³

Have noticed that taste and nausea (from headaches and triptans) are major issues.⁴ There are sublingual films and tablets in various pipelines.

1 https://www.practicalpainmanagement.com/pain/headache/meet-migraine-game-changers
2 https://endpts.com/allergan-set-to-...-as-the-battle-for-formulary-coverage-begins/
3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937501/
4 https://www.mdlinx.com/neurology/article/1519